"Careers outside academia: How her PhD helps Woojin Lee give legal advice to bioscience companies" (Article from Editage Insights)

-

 





An article written by Editage insights, on "Careers outside academia: How her PhD helps Woojin Lee give legal advice to bioscience companies". 

Link shared below:

Link  

Comments

Post a Comment

Popular posts from this blog

South Korea's Telemedicine Industry, where are we at?

-
Image
The Korean telemedicine industry has been experiencing significant growth and transformation, spurred by advancements in technology and changes in healthcare delivery models. Although so far, South Korea's regulatory environment has not been so friendly for the telemedicine industry, limiting the scope of telemedicine services, there have been many efforts to expand telemedicine regulations to accommodate technological advancements and changing healthcare needs. During the COVID pandemic, this unprecedented experience has accelerated the adoption of telemedicine globally, including in South Korea. As social distancing measures and lockdowns restricted in-person healthcare visits, telemedicine emerged as a crucial alternative for patients to receive medical advice and treatment while minimizing the risk of virus transmission. As a result, the South Korean government has recognized the potential benefits of telemedicine in improving healthcare accessibility, especially in remote area...
Read more

New roles for South Korea's 'Convergence AI Institute for Drug Discovery'

-
Image
Earlier this year, The 'Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA)' officially launched the 'Convergence AI Institute for Drug Discovery(CAIID)' and held the grand opening ceremony on January 31st. The South Korean CAIID aims to serve as a hub for jointly planning and executing digital convergence research and aims to establish safe utilization platform for diverse data, which may enhance the performance of AI.  The CAIID's head Hwajong Kim stated, "Currently, pharmaceutical companies are collaborating individually with AI companies. However, there is no perfect match between the data held by pharmaceutical companies and the advantages of each solution provider." He continued, "Since each pharmaceutical company possesses different data, the approach to AI should also vary. However, at this point, we cannot predict this in advance, which limits us." He emphasized, "It is not a stage to debate whether this business wi...
Read more